Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2412345...1020...Last »

ASCO15: Tiny Clovis Oncology Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women

June 1, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor Boulder, Colo.-based Clovis Oncology (CLVS) has become an even more attractive takeover target after it presented data Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago that showed its ovarian cancer drug shrunk tumors in 82 percent of the […]

Read More »

Germany Passes Japan To Have World’s Lowest Birth Rate, Study

A study says Germany’s birth rate has slumped to the lowest in the world, prompting fears labour market shortages will damage the economy. Germany has dropped below Japan to have not just the lowest birth rate across Europe but also globally, according to the report by Germany-based analysts. Its authors warned of the effects of […]

Read More »

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one year, Opdivo demonstrated an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival […]

Read More »

Celldex vaccine helps brain cancer patients live longer: study

Adding an experimental Celldex Therapeutics Inc vaccine that enlists the immune system to fight cancer to standard therapy helped patients with the deadliest type of brain cancer live longer, according to data from a midstage trial presented on Sunday. In the trial of 73 patients whose glioblastoma multiforme (GBM) had recurred after prior therapy, 30 […]

Read More »

Combination of Novartis drugs Tafinlar and Mekinist shows significant survival benefit in patients with metastatic melanoma

EAST HANOVER, N.J., May 31, 2015 /PRNewswire/ — Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar monotherapy alone. This is the first combination of BRAF/MEK inhibitors […]

Read More »

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

RIDGEFIELD, Conn., May 31, 2015 /PRNewswire/ — Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly […]

Read More »

Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

SUNNYVALE, Calif., May 31, 2015 /PRNewswire/ — Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA®) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. The data will be presented today at the […]

Read More »

17% Of Our Genetic Knowledge Is Wrong

Your genes are not your fate. Nonetheless, genes can tell us a lot about our risk for disease, and sometimes they can tell us how to lead healthier lives. The landscape of the human genome is vast and mostly unexplored. There is far, far more that we don’t know than we do know. This is […]

Read More »

Bristol-Myers Squibb Has A Cancer Breakthrough. Here’s Why It Should Cut The Price

A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin’s life, but it also landed him in the hospital. McLaughlin, 75, developed melanoma, the deadly skin cancer, just as he was retiring for real. He’d quit his job as a hospital administrator at 70, but spent two years helping his wife run her quilting store before […]

Read More »

China capital to roll out tough anti-smoking laws

Beijing will ban smoking in restaurants, offices and on public transport from Monday, part of unprecedented new curbs welcomed by anti-tobacco advocates, though how they will be enforced remains to be seen. Health activists have pushed for years for stronger restrictions on smoking in China, the world’s largest tobacco consumer, which is considering further anti-smoking […]

Read More »

Studies Try To Find The Right Doses Of Our Favorite Drugs: Coffee And Alcohol

The world’s most-used stimulant and best-loved depressant – caffeine and alcohol, respectively – have shared an interesting phenomenon in recent years: They’ve both moved from the probably-not-healthy-but-socially-acceptable category to the probably-healthy-in-moderation-because-science-says-so category. Based on the scientific evidence of the last decade or two, coffee is now believed to reduce risk of everything from Parkinson’s and Alzheimer’s […]

Read More »

Eisai drug extends survival in patients with rare cancers

A drug made by Japan’s Eisai Co that was originally derived from sea sponges helped extend lives of patients with soft-tissue cancers known as sarcomas by two months, a significant advance for these rare cancers with few treatment options, Belgian researchers said on Saturday. The researchers studied the drug, known as eribulin, in 452 patients […]

Read More »

J&J multiple myeloma drug offers hope after others stop working: study

An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday. J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab […]

Read More »

Pfizer’s Ibrance drug slows progression of breast cancer

A Phase III trial of Pfizer Inc’s Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance and AstraZeneca Plc’s Faslodex (fulvestrant), a widely used treatment to […]

Read More »

Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

CHICAGO, May 30, 2015 /PRNewswire/ — Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA®) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or […]

Read More »

Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival

WOODCLIFF LAKE, N.J., May 30, 2015 /PRNewswire/ — Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study’s primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. These data will be presented […]

Read More »

Genetic glitch can predict response to new class of cancer drugs

Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more likely to respond to a new class of drugs such as Merck & Co’s Keytruda, which enlist the immune system to attack tumors, a new study has shown. The small study, financed not by Big […]

Read More »

Bristol-Myers sues immunotherapy exec who left for AstraZeneca

Bristol-Myers Squibb has sued a top cancer immunotherapy executive for violating confidentiality and non-compete agreements after he left for direct competitor AstraZeneca, court documents show The suit, filed in Delaware’s Court of Chancery late on Thursday, said that David Berman violated agreements that prevented him from using confidential and trade secret information when he accepted […]

Read More »

Antibiotic approved for treating infant abdominal infections

The antibiotic meropenem was approved by the U. S. Food and Drug Administration for treating abdominal infections in children less than 3 months of age. The approval came after a study by a National Institutes of Health research network evaluated the drug in treating children in this age group.The May 28 issue of The Federal […]

Read More »

Merck immunotherapy appears effective in head and neck cancer-study

A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday. A quarter of the 132 patients who received the drug, Keytruda (pembrolizumab), saw their tumors shrink […]

Read More »

Page 1 of 2412345...1020...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation